Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$573 Mln
Revenue (TTM)
$158 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2
Industry P/E
73.01
EV/EBITDA
-7.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.7
Face value
--
Shares outstanding
40,637,000
CFO
$-223.21 Mln
EBITDA
$-231.58 Mln
Net Profit
$-10.26 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rxsight Inc (RXST)
| -59.7 | -2.3 | -47.7 | -75.3 | -1.0 | -- | -- |
|
BSE Sensex
| 4.1 | -1.1 | 9.8 | 5.8 | 16.6 | 19.4 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
|---|---|---|---|
|
Rxsight Inc (RXST)
| -14.6 | 218.2 | 12.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rxsight Inc (RXST)
|
13.9 | 572.6 | 158.4 | -26.6 | -11.6 | -9.5 | -- | 2.0 |
| 13.3 | 8,960.8 | 6,685.2 | 715.6 | 16.4 | 12.3 | 12.6 | 1.5 | |
| 250.1 | 6,628.2 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 1.0 | |
| 232.0 | 6,318.9 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 0.9 | |
| 57.4 | 7,968.4 | 2,510.8 | 185.6 | 8.8 | 4.5 | 43.7 | 1.9 | |
| 71.1 | 8,845.4 | 12,669.0 | 407.0 | 5.4 | 11.8 | 22 | 2.7 | |
| 162.8 | 8,812.8 | 1,973.6 | -494.5 | -11.4 | -41 | -- | 9.3 | |
| 257.0 | 10,106.3 | 1,240.1 | 42.2 | 4.1 | 3.6 | 243.8 | 8.2 | |
| 117.7 | 14,455.8 | 3,357.5 | 396.9 | 16.3 | 5.4 | 41.5 | 2.6 | |
| 117.5 | 7,084.1 | 645.7 | -25.4 | 6.8 | -1.3 | -- | 3.6 |
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that... enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. Address: 100 Columbia, Aliso Viejo, CA, United States, 92656 Read more
President, CEO & Director
Dr. Ronald M. Kurtz M.D.
President, CEO & Director
Dr. Ronald M. Kurtz M.D.
Headquarters
Aliso Viejo, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Rxsight Inc (RXST) stood at $ 336 Mln as on 31-Mar-25
The share price of Rxsight Inc (RXST) is $13.87 (NASDAQ) as of 18-Jun-2025 16:00 EDT. Rxsight Inc (RXST) has given a return of -1.01% in the last 3 years.
Rxsight Inc (RXST) has a market capitalisation of $ 573 Mln as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Rxsight Inc (RXST) is 1.96 times as on 18-Jun-2025, a 46% discount to its peers’ median range of 3.61 times.
Since, TTM earnings of Rxsight Inc (RXST) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Rxsight Inc (RXST) and enter the required number of quantities and click on buy to purchase the shares of Rxsight Inc (RXST).
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. Address: 100 Columbia, Aliso Viejo, CA, United States, 92656
The CEO & director of Dr. Ronald M. Kurtz M.D.. is Rxsight Inc (RXST), and CFO & Sr. VP is Dr. Ronald M. Kurtz M.D..
There is no promoter pledging in Rxsight Inc (RXST).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,134
|
|
|
981
|
|
|
921
|
|
|
906
|
|
|
889
|
|
|
823
|
|
|
742
|
|
|
671
|
|
|
671
|
| Rxsight Inc (RXST) | Ratios |
|---|---|
|
Return on equity(%)
|
-9.54
|
|
Operating margin(%)
|
-11.55
|
|
Net Margin(%)
|
-16.76
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Rxsight Inc (RXST) was $0 Mln.
$0.37
(
